Cover Image
市場調查報告書

荷爾蒙抗性(閹割抗性、雄激素非依賴性)前列腺癌:開發中產品分析

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 255937
出版日期 內容資訊 英文 665 Pages
訂單完成後即時交付
價格
Back to Top
荷爾蒙抗性(閹割抗性、雄激素非依賴性)前列腺癌:開發中產品分析 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016
出版日期: 2016年10月12日 內容資訊: 英文 665 Pages
簡介

荷爾蒙劑沒有效果,癌症細胞持續成長的前列腺癌稱為 荷爾蒙抗性前列腺癌。癌症細胞的成長在不需睪固酮的情況發生。症狀有疲勞感,血尿,臀部、腰(脊椎)、胸部(肋骨)等疼痛,食慾不振,體重減少等,發病要素有老齡化,抽煙,遺傳等。治療有化療及放射線治療等。

本報告提供全球荷爾蒙抗性(閹割抗性、雄激素非依賴性)前列腺癌治療藥的開發趨勢調查,開發中產品的各開發階段的比較分析,藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,該部門的最新趨勢,主要企業的檢討等。

簡介

荷爾蒙抗性(閹割抗性、雄激素非依賴性)前列腺癌概要

治療藥的開發

荷爾蒙抗性(閹割抗性、雄激素非依賴性)前列腺癌:企業開發中的治療藥

在荷爾蒙抗性(閹割抗性、雄激素非依賴性)前列腺癌:大學/機關研究中的治療藥

荷爾蒙抗性(閹割抗性、雄激素非依賴性)前列腺癌:開發中產品概況

荷爾蒙抗性(閹割抗性、雄激素非依賴性)前列腺癌:企業開發中的產品

荷爾蒙抗性(閹割抗性、雄激素非依賴性)前列腺癌:大學/機關研究中的產品

荷爾蒙抗性(閹割抗性、雄激素非依賴性)前列腺癌的治療藥開發作的企業

荷爾蒙抗性(閹割抗性、雄激素非依賴性)前列腺癌:治療藥的評估

藥物簡介

荷爾蒙抗性(閹割抗性、雄激素非依賴性)前列腺癌:最近的開發平台趨勢

荷爾蒙抗性(閹割抗性、雄激素非依賴性)前列腺癌:暫停中的計劃

荷爾蒙抗性(閹割抗性、雄激素非依賴性)前列腺癌:開發中止的產品

荷爾蒙抗性(閹割抗性、雄激素非依賴性)前列腺癌:產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8504IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hormone Refractory Prostate Cancer - Pipeline Review, H2 2016, provides an overview of the Hormone Refractory Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer no longer responds to hormone therapy and growth of the cancer continues, it is called hormone resistant or hormone refractory prostate cancer. This occurs if cancer cells do not need testosterone for growth. Symptoms include fatigue, blood in the urine, pain in the hips, back (spine), chest (ribs), or other areas from cancer spread to bones, loss of appetite, or weight loss. Predisposing factors include age, smoking and family history. Treatment includes chemotherapy and radiotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hormone Refractory Prostate Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hormone Refractory Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hormone Refractory Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 9, 57, 35, 1, 36 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 2, 7 and 4 molecules, respectively for Hormone Refractory Prostate Cancer.

Hormone Refractory Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hormone Refractory Prostate Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hormone Refractory Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hormone Refractory Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hormone Refractory Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hormone Refractory Prostate Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hormone Refractory Prostate Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hormone Refractory Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview
  • Therapeutics Development
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment
  • Drug Profiles
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2016
  • Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AB Science SA, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AbbVie Inc, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Advaxis, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aeterna Zentaris Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ambrx, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Amgen Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AnGes MG, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aphios Corporation, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ARMO Biosciences, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Armour Therapeutics Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arno Therapeutics, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ArQule, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arvinas, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Asana BioSciences, LLC, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Astellas Pharma Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca Plc, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ATLAB Pharma SAS, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bayer AG, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bio-Cancer Treatment International Limited, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CellCentric Ltd, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Corcept Therapeutics Incorporated, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Corvus Pharmaceuticals, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Curevac AG, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CytoVac A/S, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by DexTech Medical AB, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endo Pharmaceuticals Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endocyte, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Errant Gene Therapeutics, LLC, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ESSA Pharma Inc, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Fujifilm Corporation, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by G1 Therapeutics, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Genentech, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Genmab A/S, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Gilead Sciences, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Glactone Pharma AB, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Hybrigenics S.A., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Immunomedics, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Io Therapeutics, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Johnson & Johnson, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Jyant Technologies, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Kura Oncology, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by MedImmune, LLC, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Mediolanum farmaceutici S.p.A., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by MEI Pharma, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Merck KGaA, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corporation, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oric Pharmaceuticals Inc, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orion Oyj, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Pfizer Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Selexel, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sotio a.s., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Supratek Pharma Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tesaro, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tiltan Pharma Ltd., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tokai Pharmaceuticals, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by UbiVac, LLC, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Viralytics Ltd., H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Zenith Capital Corp, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..1), H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..2), H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..3), H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..4), H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..5), H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..6), H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..7), H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..8), H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..9), H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..10), H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..1), H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..2), H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..3), H2 2016
  • Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..4), H2 2016

List of Figures

  • Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2016
  • Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top